MOLOGIC HAS A LONG & ENVIABLE TRACK RECORD WITH WOMEN’S HEALTH DIAGNOSTIC
With the inventor of Clearblue, the first rapid diagnostic pregnancy test, as our co-founder, Mologic has a long and enviable track record in the field of women’s health diagnostics. Rapid point-of-care diagnosis is quickly adopted in this sector thanks to the familiarity of the pregnancy test.
Women carrying bacterial vaginosis (BV) are more susceptible to STDs and transmitting disease (including HIV) and are at increased risk of early miscarriage or complications during pregnancy. BV is treated with an antibiotic, and is five times more prevalent than thrush, a yeast infection caused by the fungus Candida, which is treated with an antifungal. Misdiagnosing and prescribing the wrong treatment can make either condition worse.
Urinary Tract Infections (UTIs) are common, affecting around 150 million patients worldwide and leading to over 2 million hospitalisations. Current diagnostics are time consuming and potentially inaccurate.
Diagnostic tests in development include:
BVPro is a rapid test for bacterial vaginosis which uses a vaginal swab to test for enzyme activity.
BVThrush Combi is a rapid test which uses a vaginal swab to detect enzyme activity, enabling diagnosis and differentiation between BV and candidiasis.
UTRiPLEX enables rapid diagnosis of UTIs via a urine test for host response biomarkers. (Triplex.)